CHM

0.00%

2.2¢

CHIMERIC THERAPEUTICS LIMITED

Market Cap $18.84M Add to my watchlist

Healthcare Biotechnology

Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company.... Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company. The Company is focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its pipeline includes CHM 1101 and CHM 2101. Its CHM 1101 (CLTX CAR-T) is a CAR-T therapy developed for the treatment of patients with solid tumors. CHM-1101 is being studied in a Phase 1B clinical trial in recurrent/ progressive glioblastoma. CHM 2101 is a third generation CDH17 CAR T, which is in preclinical development with a planned Phase I clinical trial in neuroendocrine tumors, colorectal, pancreatic and gastric cancer. Its pipeline also includes the CORE-NK platform, a clinically validated, off-the-shelf natural killer (NK) cell therapy platform to their portfolio (CHM 0201). The Company is also focused on the development of NK and CAR NK assets with plans for Phase 1B clinical trials in solid tumors and blood cancers.More

BlinkLab Limited (ASX: BB1) is a trailblazer in digital healthcare, leveraging AI and machine learning in mobile applications to revolutioniSe neurodevelopmental condition diagnosis like ASD and ADHD. Born from extensive research at Princeton University,...

Latest Threads

Tag

Subject

CHM

Ann: Notice of Extraordinary General Meeting/Proxy Form

23/05/24

110

26K

23/05/24

Last post NZ Trader

110

26K

CHM

Ann: CHM CDH17 Phase 1/2 clinical trial approved for initiation

23/05/24

5.0K

23/05/24

Last post NZ Trader

5.0K

CHM

Ann: Resignation of CEO and Managing Director

22/05/24

19K

22/05/24

Last post KrushingIt

19K

CHM

Ann: Chimeric opens CHM CDH17 Phase 1/2 trial

22/05/24

2.8K

22/05/24

Last post KrushingIt

2.8K

CHM

Ann: CHM CORE-NK vactosertib Phase 1b study re-opens enrolment

22/05/24

3.8K

22/05/24

Last post pinch2020

3.8K

CHM

Chimeric: Media Thread

10 11 12

19/05/24

694

279K

19/05/24

Last post KrushingIt

694

279K

CHM

Ann: FDA clearance of IND for CHM 2101

19/05/24

22K

19/05/24

Last post gavint66

22K

CHM

Ann: 1st patient dosed in CHM 0201 Vactosertib trial

16/05/24

7.3K

16/05/24

Last post ma420

7.3K

See All Discussions

Timeline

Chimeric opens CHM CDH17 Phase 1/2 trial
22 May 10:14	Share

CHM CDH17 Phase 1/2 clinical trial approved for initiation
20 May 09:00	Share

CHM CORE-NK vactosertib Phase 1b study re-opens enrolment
16 May 09:27	Share

Notification regarding unquoted securities - CHM
13 May 17:09	Share

Notice of Extraordinary General Meeting/Proxy Form
13 May 09:01	Share

Notice under section 708A
02 May 17:39	Share

Application for quotation of securities - CHM
02 May 17:34	Share

Dr Rebecca McQualter appointed COO
02 May 09:59	Share

Resignation of CEO and Managing Director
01 May 09:54	Share

Quarterly Activities/Appendix 4C Cash Flow Report
30 Apr 09:33	Share

Change of Director's Interest Notice PH
08 Apr 17:03	Share

Change of Director's Interest Notice PH
08 Apr 17:00	Share

US patent allowed for CHM 0201 (CORE-NK) technology
05 Apr 08:50	Share

Notification of cessation of securities - CHM
02 Apr 16:58	Share

Notice under section 708A
28 Mar 16:56	Share

Application for quotation of securities - CHM
28 Mar 16:51	Share

Chimeric to present at NWR Virtual Healthcare Conference
15 Mar 08:21	Share

Clinical milestones for 2024 & 2023 successes highlighted
14 Mar 09:58	Share

Notification of cessation of securities - CHM
07 Mar 16:34	Share

Notice under section 708A
29 Feb 09:48	Share

Half Yearly Report and Accounts
29 Feb 08:19	Share

Application for quotation of securities - CHM
28 Feb 11:49	Share

Chimeric to present at ShareCafe Hidden Gems webinar
28 Feb 09:33	Share

Late lodgement of Appendix 3Y
15 Feb 18:40	Share

1st patient treated in ADVENT-AML Phase 1b clinical trial
08 Feb 09:16	Share

Quarterly Activities/Appendix 4C Cash Flow Report
31 Jan 10:51	Share

Application for quotation of securities - CHM
24 Jan 11:43	Share

Investor Presentation
18 Jan 11:39	Share

Placement of Entitlement Offer Shortfall
18 Jan 11:34	Share

ADVENT-AML Phase 1B clinical trial open to enrolment
15 Jan 09:59	Share

View More

(20min delay)
Last 2.2¢		Change 0.000(0.00%)		Mkt cap ! $18.84M

Open	High	Low	Value	Volume
2.3¢	2.3¢	2.2¢	$32.17K	1.462M

Buyers (Bids)

No.	Vol.	Price($)
3	849848	2.2¢

Sellers (Offers)

Price($)	Vol.	No.
2.3¢	340404	8

View Market Depth

No.	Vol.	Price($)
3	849848	0.022
12	1132889	0.021
14	1388350	0.020
3	318157	0.019
3	205500	0.018

Price($)	Vol.	No.
0.023	340404	8
0.024	350000	2
0.025	597500	1
0.026	793692	4
0.027	2198333	6

Last trade - 14.57pm 24/05/2024 (20 minute delay)


Last 2.2¢		Change 0.000 ( 0.00 %)
Open	High	Low	Volume
2.2¢	2.2¢	2.2¢	373920
Last updated 15.01pm 24/05/2024 ?

CHM (ASX) Chart

CHIMERIC THERAPEUTICS LIMITED

Latest Threads

Australian-listed companies chase the rainbow of the renewable energy market

Timeline

Featured News

Latest Articles

Chimeric Therapeutics treats first patient in Advent-AML phase 1B clinical trial

Chimeric Therapeutics (ASX:CHM) has treated the first patient in its Advent-AML phase 1B clinical trial at The University of Texas MD Anderson Cancer Center.

Chimeric Therapeutics announces positive preclinical data for CHM 1301

Chimeric Therapeutics (ASX:CHM) has announced positive in vitro data for CHM 1301, the company's next-generation CLTX CAR NK cell therapy program.

Chimeric Therapeutics to raise $10m through entitlement offer

Chimeric Therapeutics (ASX:CHM) has announced it will conduct an equity raising through a two-for-three entitlement offer of new shares, with the goal of raising up to $10 million.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News